Evidence Level
Hydrolyzed type II collagen is supported by a moderate evidence base for joint health. Clark et al. (2008) demonstrated significant reduction in activity-related joint pain in athletes with 10g/day over 24 weeks. Bruyere et al. (2012) showed benefits in knee OA patients at a lower 1,200mg dose. The meta-analysis by Zhu et al. (2018) analyzing 5 RCTs confirmed statistically significant improvements in WOMAC scores with collagen supplementation. The mechanism is distinct from UC-II: hydrolyzed type II collagen provides bioactive peptides (particularly prolyl-hydroxyproline and hydroxyprolyl-glycine) that are absorbed intact and accumulate in cartilage, where they stimulate chondrocytes to produce new type II collagen and proteoglycans. Taking collagen with vitamin C further enhances this process by supporting the hydroxylation of proline residues essential for collagen structure.